ARTIVION, INC.

Rule 10b5-1 Trading Arrangements

On December 10, 2025 Amy D. Horton, our Chief Accounting Officer, adopted a Rule 10b5-1 trading arrangement, pursuant to which she may sell up to 10,660 shares of the Company’s common stock. The duration of the trading arrangement is from March 11, 2026 to February 19, 2027. This trading arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.

No other directors or officers (as defined in Rule 16a-1(f) under the Exchange Act)adopted, modified, orterminated the contracts, instructions, or written plans for the purchase or sale of the Company’s securities during the three months ended December 31, 2025.

Marshall S. Stanton Retirement and Role as Advisor

As previously disclosed pursuant to the Form 8-K filed by the Company on August 11, 2025, Marshall S. Stanton, M.D., the Company’s Senior Vice President, Clinical Research and Chief Medical Officer, notified the Company of his decision to retire, effective March 31, 2026, from the position of Senior Vice President, Clinical Research and Chief Medical Officer.

To assist the Company in the transition following Dr. Stanton’s retirement, the Company and Dr. Stanton entered into a letter agreement on February 16, 2026, pursuant to which Dr. Stanton will remain employed on a part-time basis as a senior advisor to the Company’s Chief Executive Officer for a one-year period beginning on April 1, 2026. The Company will pay Dr. Stanton $1,300 per month for such services and he will otherwise be eligible to participate in any of the Company’s benefit programs available to part-time employees.